Paper Details

  1. Home
  2. Paper Details

Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer.

Author: OuSai-Hong Ignatius

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This article discusses crizotinib, an oral small-molecule RTK inhibitor, approved for treating ALK-rearranged non-small-cell lung cancer (NSCLC). It highlights the drug's efficacy, side effects, and ongoing confirmatory trials.
Paper Details　
Original Abstract of the Article :
Crizotinib (Pfizer, CA, USA) is an oral small-molecule RTK inhibitor that targets ALK and MET, and potentially other RTKs. Crizotinib was approved by the US FDA on 26 August 2011 for the treatment of ALK-rearranged non-small-cell lung cancer (NSCLC), as detected by ALK break-apart FISH assay. This c...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1586/era.11.186

データ提供：米国国立医学図書館（NLM）

Crizotinib: Targeting a Unique Molecular Subset of Non-Small-Cell Lung Cancer

[Lung cancer] is a formidable foe, and the quest for effective treatments is a continuous journey through the desert of research. This study focuses on a new drug called [crizotinib], which specifically targets a unique molecular subset of [non-small-cell lung cancer] known as [ALK-rearranged NSCLC]. It's like finding a specific water source in a vast and arid landscape, targeting a unique need.

Crizotinib: A Beacon of Hope for ALK-Rearranged NSCLC

[Crizotinib] has been approved by the [FDA] for the treatment of [ALK-rearranged NSCLC], based on promising results in clinical trials that demonstrated a response rate of [50-61%]. These findings are like finding a hidden oasis in the middle of the desert - a source of relief and hope for patients with this specific type of cancer. [Crizotinib] has shown to be generally well-tolerated, with the most common side effects being [grade 1-2 gastrointestinal events], [edema], and [fatigue].

Crizotinib: A Promising Future in Lung Cancer Treatment

This study underscores the importance of targeted therapy in [lung cancer] and the remarkable progress being made in developing innovative treatments. [Crizotinib] represents a significant step forward in the fight against [ALK-rearranged NSCLC], offering a ray of hope for patients who may have previously had limited treatment options. It's like finding a new way to channel water through a desert, bringing life and hope to an otherwise arid landscape.

Dr. Camel's Conclusion

The discovery of [crizotinib] is a testament to the ingenuity and dedication of scientists in the field of [cancer research]. By understanding the molecular mechanisms underlying [lung cancer], researchers are able to develop targeted treatments that offer a more personalized and effective approach to combatting this disease. As we continue to explore the intricate pathways of [lung cancer], we may uncover even more promising therapies in the years to come.
Date :
  1. Date Completed 2012-10-01
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

22316363

DOI: Digital Object Identifier

10.1586/era.11.186

Related Literature

Article Analysis
・Side Effects of crizotinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.